Abstract
Patients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a potential therapeutic target, we systematically evaluated methods of assessing EGFR amplification by multiple assays. Specifically, we evaluated correlation among fluorescence in situ hybridization (FISH), a standard assay for detecting EGFR amplification, with other methods.Experimental Design: Formalin-fixed, paraffin-embedded tumor samples were used for all assays. EGFR amplification was detected using FISH (N = 206) and whole-exome sequencing (WES, N = 74). EGFR mRNA expression was measured using reverse transcription-polymerase chain reaction (RT-PCR, N = 206) and transcriptome profiling (RNAseq, N = 64). EGFR protein expression was determined by immunohistochemistry (IHC, N = 34). Significant correlations among various methods were determined using Cohen's kappa (κ = 0.61-0.80 defines substantial agreement) or R 2 statistics. EGFR mRNA expression levels by RNA sequencing (RNAseq) and RT-PCR were highly correlated with EGFR amplification assessed by FISH (κ = 0.702). High concordance was also observ...Continue Reading
References
Jan 10, 1985·Nature·T A LibermannJ Schlessinger
Jan 1, 1994·Journal of Neuro-oncology·J SchlegelM Kiessling
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Dec 14, 2007·Proceedings of the National Academy of Sciences of the United States of America·Rameen BeroukhimWilliam R Sellers
Jan 29, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Koji YoshimotoPaul S Mischel
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Mar 25, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Valsamo K AnagnostouDavid L Rimm
Nov 8, 2011·The Lancet Oncology·Robert PirkerKenneth J O'Byrne
Jun 20, 2013·The FEBS Journal·Hui K GanTerrance G Johns
Oct 15, 2013·Cell·Cameron W BrennanUNKNOWN TCGA Research Network
Jul 8, 2015·Journal of Translational Medicine·Ryan A HutchinsonPeter W Hamilton
Oct 28, 2017·Cancer Chemotherapy and Pharmacology·Martin van den BentDavid A Reardon
Oct 28, 2017·Neuro-oncology·Hui K GanPriya Kumthekar
Mar 14, 2018·Cancer·Glenwood D GossAnthony W Tolcher
Jul 10, 2018·Neuro-oncology·Andrew B LassmanRyan Merrell
Citations
Mar 20, 2020·Investigational New Drugs·James M ClearyAnthony W Tolcher
Mar 3, 2020·Neuro-oncology Advances·Matthew S JiAlbert Lai
Oct 19, 2019·Acta Neuropathologica Communications·Arne ChristiansChristian Hartmann
Jul 10, 2020·Neuro-oncology Advances·Youri HoogstratePim J French
Jul 6, 2019·Journal of Neuro-oncology·Andrew B LassmanMartin J van den Bent
Jan 23, 2020·Cancers·María González-TablasMaría Dolores Tabernero
Sep 23, 2019·Journal of Neuro-oncology·Daniel I HoffmanStephen J Bagley
Nov 12, 2020·Cells·Lara NavarroConcha López-Ginés
May 1, 2021·Cancers·Sara FranceschiChiara Maria Mazzanti
Apr 30, 2021·Neurosurgery·Yae Won ParkSeung-Koo Lee
Aug 3, 2021·Brain Tumor Pathology·Seong-Ik KimJae-Kyung Won
Aug 27, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suresh S RamalingamJulien Mazieres
Sep 1, 2021·Journal of Translational Medicine·Hua-Fu ZhaoWei-Ping Li